Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma


Balcik O. S. , Albayrak M., Uyar M. E. , Dagdas S., Yokus O., Ceran F., ...More

Blood Coagulation and Fibrinolysis, vol.22, no.4, pp.260-263, 2011 (Journal Indexed in SCI Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 4
  • Publication Date: 2011
  • Doi Number: 10.1097/mbc.0b013e3283442cf9
  • Title of Journal : Blood Coagulation and Fibrinolysis
  • Page Numbers: pp.260-263
  • Keywords: multiple myeloma, prognostic factors, thrombin activatable fibrinolysis inhibitor

Abstract

Multiple myeloma has been associated with the development of thromboembolic events. Thrombin activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase B-like proenzyme, which potently inhibits fibrinolysis. The purpose of the present study was to assess the TAFI levels in patients with newly diagnosed multiple myeloma. Twenty-seven newly diagnosed multiple myeloma patients (16 women and 11 men) and 27 age-matched healthy individuals (14 women and 13 men) were included in the study. Serum TAFI levels were significantly increased in patients with multiple myeloma (46 ± 13. 3 vs. 36. 6 ± 9.7 μg/ml) compared with healthy individuals. Serum TAFI levels were negatively correlated with serum albumin (CC: -0.453, P < 0.05) and hemoglobin levels (CC: -0.392, P < 0.05) and positively correlated with the β-2 microglobulin levels (CC: 0.524, P < 0.05). In this study, we observed significantly elevated TAFI levels in patients with multiple myeloma and higher serum TAFI levels were suggested to be associated with higher disease stage. With these results, a possible role of elevated TAFI levels in thromboembolic manifestations in the course of multiple myeloma can be suggested. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.